patients: a randomized, multicenter phase III trial // Ann. Oncol. — 1994 V. 5 (Suppl. 7). —
P. 41 44.
Conte P.F., Latreille J., Mauriac L., Calabresi F., Santos R., Campos D., Bonneterre
J., Francini G., Ford J.M.
// Delay in progression of bone metastases in breast cancer
patients treated with intravenous pamidronate: results from a multinational randomized
controlled trial. The Aredia Multinational Cooperative Group // J. Clin. Oncol. — 1996.
— V. 14(9). — P. 2552 2559.
Coombes R.C., Dady P., Parson C.
è ñîàâò. Assessment îf response of bone metas
tases to systemic treatment in patient with breast cancer // Cancer. — 1983. — V. 52. — P.
610 614.
Coombes R.C., Haynes B.P., Dowsett M.,
è ñîàâò. Idoxifene: report of a phase I study
in patients with metastatic breast cancer // Cancer Res. — 1995. — V. 55. — P. 1070 1074.
Cooper P.R., Errico T.J., Martin R.,
è ñîàâò. A systematic approach to spinal recon
struction after anterior decompression for neoplastic disease of thoracic and lumbar spine
// Neurosurg. — 1993. — V. 32 — P. 1 8.
Cooper R.G.
Combination chemotherapy in hormoneresistant breast cancer // Proc.
Am. Assoc. Res. — 1969. — V.10. 15p.
Creagan E. T.,Wilkinson J. M.
Pain relief in terminali ill patients // Am. Fam.
Physician. — 1989. — V.40(6). — P.133 140.
Creech R.
An effective low dose intermittent cyclophosphamide, methotrexate and
5 fluorouracil treatment regimen for metastatic breast cancer // Cancer. — 1975. —V. 35. —
P. 1101 1107.
Crone+Munzebrock R.P.
Quantification of recalcificatoin of irradiated vertebral body
osteolyses by dual energy computed tomography // Eur. J. Radiol. — 1987. — V. 7. —
P.1 5.
Cullen K.J., Yee D., Sly W.S.,
è ñîàâò. Insulin like growth factor receptor expression
and function in human breast cancer // Cancer Res. — 1990. — V. 50. — P. 48 53.
Dano K., Andreasen P.A., Grondahi+Hansen J.
et. al. Plasminogen activators, tissue
degradation, and cancer // Adv. Cancer. Res. — 1985. — V. 44. — P. 139 266.
Daffner R.H., Luprtin A.R., Dash N., Deeb Z.I., Sefzek R.J., Schapiro R.L.
MRI in the
detection of malignant infiltration of bone marrow // A.J.R. — 1986. — V. 146. —
P. 353 358.
Dalen N., Edsmyr F.
Bone mineral content of the femoral neck after irradiation //
Acta Radiol. Ther. Phys. Biol. — 1974. — V. 14. — P. 139 144.
Davis H.L.
Five drug therapy in advanced breast cancer. Factors influencing toxic
ity and response // Cancer. — 1974. — V. 34. — P. 239 245.
Decker D.A.
Characterization and analysis of complete regression to chemotherapy
in metastatic breast cancer // Proc. Am. Assoc. Cancer Res. — 1979. — V. 20. — P. 241.
DeFriend D.J., Howell A., Nicholson R.I.,
è ñîàâò. Investigation of a pure antiestro
gen (ICI 182780) in women with primary breast cancer // Cancer Res. — 1994. — V.54. —
P. 408 414.
Dehdashti F., Siegel B.A., Griffeth L.K., Fusselman M.J., Trask D.D., McGuire A.H.,
McGuire D.J.
Benign versus malignant intraosseous lesions: discrimination by means of
PET with 2 [F 18]fluoro 2 deoxy D glucose // Radiology. — 1996. — V. 200(1). — P.
243 247.
De+Klerk J.M., Van+Dijk A., Van+het+Schip A.D.
Pharmacokinetics of rhenium 186
after administration of rhenium 186 HEDP to patients with bone metastases // J. Nucl.
Med. — 1992. — V. 33(5). — P. 646 651.
222
Êîñòíûå ìåòàñòàçû ðàêà ìîëî÷íîé æåëåçû
